Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cyto-MSC in acute graft-versus-host disease
NCT03847844Phase 2Completed
- Sponsor
- Cytopeutics
- Start
- Feb 2019
- Primary completion
- Jul 2023
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of Cyto-MSC in Acute Graft-Versus-Host Disease (aGvHD), sponsored by Cytopeutics. Started Feb 2019; status: completed.
02
Drugs
Cyto-MSC
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on NCT03847844.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03847844.